The Women's Health Initiative combined-therapy arm was halted in 2002 after finding excess breast cancer, stroke and cardiovascular events — in a cohort averaging 63 years old, many more than a decade past menopause, taking one specific oral regimen (conjugated equine estrogens plus medroxyprogesterone). Those findings were broadcast as applying to every woman, every formulation and every age. Hormone therapy use collapsed from roughly 40% of eligible women to under 5%, and a generation of clinicians stopped learning to prescribe it. The 2003 black-box warning cemented a risk message that later evidence — including WHI's own 18-year follow-up showing no excess all-cause mortality — steadily undermined.

Systemic estrogen (with a progestogen for women with a uterus) is the most effective treatment in existence for vasomotor symptoms — hot flashes and night sweats — and prevents the accelerated bone loss of early menopause, with WHI itself showing fewer fractures. Low-dose vaginal estrogen treats genitourinary symptoms with negligible systemic absorption and no demonstrated cancer excess across dozens of trials; professional bodies had argued for years that its inclusion under the black-box warning was scientifically indefensible. For symptomatic women under 60 or within ten years of menopause, benefits generally exceed risks — the position of the Menopause Society since 2022, now reflected in US labelling.

On 10 November 2025 the FDA announced removal of black-box warnings from estrogen-containing menopause products — systemic and vaginal — citing outdated generalisation of WHI findings, with rewritten age-specific labels emphasising initiation before 60 or within ten years of menopause. The endometrial-cancer warning on systemic estrogen-alone therapy for women with a uterus remains, an important nuance widely lost in coverage. The announcement, made by the HHS Secretary and FDA Commissioner at a political press event, drew a two-sided reaction: menopause specialists welcomed the correction while ACOG and oncology bodies cautioned that systemic therapy retains real risks and that individualised counselling is still mandatory.

The strongest open question is whether starting hormone therapy early in menopause protects the heart and brain — the 'timing hypothesis'. Observational data and WHI age-stratified analyses are suggestive (estrogen-alone therapy in younger women showed reduced breast cancer, HR 0.79, and no coronary excess), but no trial has been designed to prove prevention benefit prospectively, and using hormone therapy solely to prevent cardiovascular disease or dementia remains outside every major guideline. Duration of use, extended use past 60 in women who remain symptomatic, and risk in specific subgroups are genuinely unsettled — which is different from being disproven.

Within days of the FDA announcement, social platforms filled with claims that hormone therapy is protective for heart, brain, bones and ageing itself — the 1990s prevention narrative reborn, this time monetised through telehealth subscriptions and compounded 'bioidentical' products that regulators have never evaluated. The historical irony is complete: the same pendulum dynamics that overstated harm for twenty years are now overstating benefit, and compounded hormone preparations — untested, unstandardised, aggressively marketed — occupy the space that evidence-based products vacated. Correcting an overcorrection with another overcorrection is the signature failure mode of this entire field.

A symptomatic woman under 60 or within ten years of menopause has good evidence that hormone therapy is effective and, for most, safe — the decision is individual, weighing personal breast-cancer, clot and cardiovascular history, and favouring transdermal estrogen where clot risk matters. Vaginal estrogen for genitourinary symptoms is safe for nearly everyone, including many cancer survivors in oncology consultation. Hormone therapy purely as an anti-ageing or disease-prevention strategy is not evidence-based, and compounded bioidentical products carry the risks of hormone therapy without the quality control. The right response to twenty years of unjustified fear is accuracy, not euphoria.